S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
Log in
NASDAQ:BLRX

BioLineRx Stock Forecast, Price & News

$3.16
+0.07 (+2.27 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.11
Now: $3.16
$3.38
50-Day Range
$2.38
MA: $3.11
$4.00
52-Week Range
$1.06
Now: $3.16
$4.23
Volume930,568 shs
Average Volume2.81 million shs
Market Capitalization$123.41 million
P/E RatioN/A
Dividend YieldN/A
Beta2.08
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with KEYTRUDA (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's TECENTRIQ (Atezolizumab) in Phase 1b/2 studies for solid tumors. BioLineRx Ltd. was founded in 2003 and is headquartered in Modi'in, Israel.
BioLineRx logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BLRX
CUSIPN/A
Phone972-8642-9100
Employees42
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.46 per share

Profitability

Net Income$-25,450,000.00

Miscellaneous

Market Cap$123.41 million
Next Earnings Date5/19/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

363rd out of 1,966 stocks

Pharmaceutical Preparations Industry

181st out of 772 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
$3.16
+0.07 (+2.27 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLRX News and Ratings via Email

Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioLineRx (NASDAQ:BLRX) Frequently Asked Questions

Is BioLineRx a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioLineRx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BioLineRx stock.
View analyst ratings for BioLineRx
or view top-rated stocks.

What stocks does MarketBeat like better than BioLineRx?

Wall Street analysts have given BioLineRx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioLineRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting BioLineRx?

BioLineRx saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 1,790,000 shares, a drop of 27.8% from the January 14th total of 2,480,000 shares. Based on an average daily volume of 2,550,000 shares, the short-interest ratio is currently 0.7 days.
View BioLineRx's Short Interest
.

When is BioLineRx's next earnings date?

BioLineRx is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for BioLineRx
.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) posted its quarterly earnings results on Monday, November, 23rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.06.
View BioLineRx's earnings history
.

How has BioLineRx's stock been impacted by COVID-19 (Coronavirus)?

BioLineRx's stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BLRX shares have increased by 97.5% and is now trading at $3.16.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BLRX?

2 Wall Street analysts have issued 12 month target prices for BioLineRx's stock. Their forecasts range from $11.00 to $19.00. On average, they anticipate BioLineRx's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 374.7% from the stock's current price.
View analysts' price targets for BioLineRx
or view top-rated stocks among Wall Street analysts.

Who are BioLineRx's key executives?

BioLineRx's management team includes the following people:
  • Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA, Chief Exec. Officer (Age 61, Pay $469k)
  • Ms. Mali Zeevi CPA, CPA, Chief Financial Officer (Age 45, Pay $274k)
  • Dr. Ella Sorani, VP R&D (Age 53, Pay $301k)
  • Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 46, Pay $299k)
  • Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 69)
  • Mr. Raziel Fried, Treasurer & Budgetary Control Director
  • Dr. Leah N Klapper, Consultant (Age 56)

Who are some of BioLineRx's key competitors?

What other stocks do shareholders of BioLineRx own?

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a number of institutional and retail investors. Top institutional shareholders include LPL Financial LLC (0.11%), Thomasville National Bank (0.09%) and Rhumbline Advisers (0.04%).

Which institutional investors are buying BioLineRx stock?

BLRX stock was purchased by a variety of institutional investors in the last quarter, including LPL Financial LLC, Rhumbline Advisers, and Thomasville National Bank.

How do I buy shares of BioLineRx?

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $3.16.

How much money does BioLineRx make?

BioLineRx has a market capitalization of $123.41 million. The biotechnology company earns $-25,450,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis.

How many employees does BioLineRx have?

BioLineRx employs 42 workers across the globe.

What is BioLineRx's official website?

The official website for BioLineRx is www.biolinerx.com.

Where are BioLineRx's headquarters?

BioLineRx is headquartered at 2 HAMA-AYAN STREET, MODI-IN L3, 7177871.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected]


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.